July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Brian Rini: KIM-1 is a novel prognostic and predictive biomarker in RCC
Jun 9, 2024, 02:45

Brian Rini: KIM-1 is a novel prognostic and predictive biomarker in RCC

Toni Choueiri shared a post by Brian Rini, Chief of Clinical Trials at Vanderbilt University, on X/Twitter:

KIM1 seems to be quite a promising kidney cancer biomarker from screening, recurrence, and selecting therapy. Our team Harvard Medical School, Brigham and Women’s Hospital and Dana-Farber Cancer Institute has been working on this as part of DF/HCC for decades (Dr. Bonventre) + past 5 years in RCC with Wenxin Xu leading the charge and his mentors (Bhatt/McDermott/Bonventre).”

Quoting Brian Rini’s post:

KIM-1 is a novel prognostic and predictive biomarker in the adjuvant RCC space. Great data at ASCO24 and stellar discussion by Wenxin Xu (Academy of Kidney Cancer Investigators member!). We discuss the KIM-1 data with Laurence Albiges.”

Further information.
Source: Toni Choueiri/X and Brian Rini/X

Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director of International Strategic Initiatives at Dana-Farber and past President of the Medical Staff at DFCI (2016-2018).

He received the George Canellos Award for Excellence in Clinical Investigation and Patient Care from DFCI in 2013, the Eugene Schonfeld Award from the Kidney Cancer Association (KCA) in 2016, and is a 2021 Giants of Cancer Care inductee. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, KidneyCan Board, the National Cancer Institute (NCI) GU Steering Committee, and is past Chairman (2015-2018) of the Medical and Scientific Steering Committee of the KCA.

Dr. Choueiri is an elected member of the American Society of Clinical Investigation (ASCI). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania.